Saturday, February 25, 2023 9:33:24 PM
https://www.alvotech.com/
We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives.
It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars.
Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission.
We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
Recent ALVO News
- Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 • GlobeNewswire Inc. • 05/02/2024 11:15:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/30/2024 08:00:00 AM
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) • GlobeNewswire Inc. • 04/24/2024 08:00:00 AM
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/19/2024 10:10:00 AM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • Business Wire • 04/16/2024 09:43:00 PM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 04/16/2024 09:30:00 PM
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 • GlobeNewswire Inc. • 04/03/2024 11:41:03 AM
- Alvotech Announces Increase in Number of Own Shares • GlobeNewswire Inc. • 03/22/2024 08:15:00 PM
- Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update • GlobeNewswire Inc. • 03/20/2024 08:15:00 PM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET • GlobeNewswire Inc. • 03/05/2024 09:00:00 PM
- Alvotech Appoints Interim Chief Quality Officer • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share • GlobeNewswire Inc. • 02/26/2024 09:25:00 AM
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® • GlobeNewswire Inc. • 02/24/2024 01:15:09 AM
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® • Business Wire • 02/24/2024 01:15:00 AM
- Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 02/15/2024 11:30:00 AM
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® • GlobeNewswire Inc. • 01/29/2024 09:00:00 AM
- Alvotech Shares Climb After FDA Concludes Facility Inspection • Dow Jones News • 01/19/2024 05:31:00 PM
- Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 • GlobeNewswire Inc. • 01/19/2024 04:30:00 PM
- STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara • GlobeNewswire Inc. • 01/10/2024 08:30:00 AM
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) • GlobeNewswire Inc. • 01/03/2024 08:30:00 AM
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® • GlobeNewswire Inc. • 11/29/2023 09:00:00 AM
- Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET • GlobeNewswire Inc. • 11/21/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM